Effects of comorbid depression on response to treatment for obsessive-compulsive disorder

Behavior Therapy

Volumn 31, Issue 3, 2000, Pages 517-528

  Abramowitz, Jonathan S ^a,c   Franklin, Martin E ^a   Street, Gordon P ^a   Kozak, Michael J ^b   Foa, Edna B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Medical College of Pennsylvania   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HABITUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034514553     PISSN: 00057894     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-7894(00)80028-3     Document Type: Article

References (26)

1. Diagnostic issues and epidemiology in obsessive-compulsive disorder
2. Predictors of improvement in obsessive-compulsive disorder
3. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
4. An inventory for measuring depression
5. A family study of obsessivecompulsive disorder
6. Predictive factors in the treatment of obsessive-compulsive disorder with fluvoxamine and or behavior therapy
7. Failure in treating obsessive-compulsives
8. Depression, habituation, and treatment outcome in obsessive-compulsives
9. Success and failure in the behavioral treatment of obsessive-compulsives
10. Emotional processing of fear: Exposure to corrective information
11. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy
12. The Yale-Brown obsessive-compulsive scale: II. Validity
13. The Yale-Brown obsessive-compulsive scale: I. Development, use, and reliability
14. Relapse prevention program for obsessive-compulsive disorder
15. A decision model in the treatment of obsessive-compulsive neurosis
16. New approaches to the treatment of obsessive-compulsive disorders
17. Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings
18. Six-year follow-up after clomipramine and exposure therapy for obsessive-compulsive disorder
19. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder
20. Depressed mood is related to obsessions but not to compulsions in obsessive-compulsive disorder
21. Social support and treatment outcome of obsessive-compulsive disorder at 9-month follow-up